Xia N, Qu S
Division of Nephrology, First Affiliated Hospital, WCUMS, Chengdu 610041, China.
Hua Xi Yi Ke Da Xue Xue Bao. 2001 Jun;32(2):300-2.
To verify the therapeutical effect of exogenous reduced glutathione (GSH) on the patients with uremic anemia.
Forty two patients with uremic anemia were randomly divided into treatment group and control group. All patients received subcutaneously recombinant human erythropoietin (r-HuEPO) at the dose of 3000U twice a week for 12 weeks. Each of the patients in the treatment group was given intravenously reduced glutathione at the dose of 1200 mg twice a week for 12 weeks. The measurements of hemoglobin, red blood cells and hematocrit were performed.
After administration of r-HuEPO, the levels of hemoglobin, red blood cells and hematocrit were significantly elevated in both treatment and control groups (P < 0.01). The levels of hemoglobin, red blood cells and hematocrit in treatment group were elevated much more obviously, compared with those in control group (P < 0.05).
These findings seem to indicate that exogenous GSH could enhance the effect of r-HuEPO on uremic anemia, and therefore it might represent a useful drug in the treatment and management of uremic anemia.
验证外源性还原型谷胱甘肽（GSH）对尿毒症贫血患者的治疗效果。
将42例尿毒症贫血患者随机分为治疗组和对照组。所有患者均接受皮下注射重组人促红细胞生成素（r-HuEPO），剂量为3000U，每周2次，共12周。治疗组患者每周静脉注射2次还原型谷胱甘肽，剂量为1200mg，共12周。测定血红蛋白、红细胞和血细胞比容。
给予r-HuEPO后，治疗组和对照组的血红蛋白、红细胞和血细胞比容水平均显著升高（P<0.01）。与对照组相比，治疗组的血红蛋白、红细胞和血细胞比容水平升高更为明显（P<0.05）。
这些结果似乎表明，外源性GSH可增强r-HuEPO对尿毒症贫血的治疗效果，因此它可能是治疗和管理尿毒症贫血的一种有用药物。
